Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 126.3% in the third quarter, Holdings Channel reports. The institutional investor owned 229,138 shares of the company’s stock after acquiring an additional 127,868 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Zentalis Pharmaceuticals were worth $843,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Anfield Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $40,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth approximately $41,000. Kennedy Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the first quarter worth approximately $189,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $58,000.

Zentalis Pharmaceuticals Stock Up 4.3 %

NASDAQ:ZNTL opened at $3.63 on Thursday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07. The company has a market capitalization of $258.67 million, a P/E ratio of -1.46 and a beta of 1.74. The stock’s fifty day moving average is $3.40 and its two-hundred day moving average is $4.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZNTL. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.